Mexico's Ministry of Health Seeks to Turn Research Into Products

Mexico's Ministry of Health has proposed strengthening the transfer of publicly funded research into patents, medical devices, and medicines, citing regulatory modernization, financing, and public-private collaboration as necessary components. The move signals a policy direction toward research commercialization at a time when multinational pharmaceutical companies are expanding clinical research investment in the country.  

Mexico's Ministry of Health called for stronger mechanisms to convert publicly funded scientific research into technologies, patents, medical devices, and medicines. Minister of Health David Kershenobich made the remarks during the 37th anniversary of the Coordinating Commission of National Institutes of Health and High Specialty Hospitals (CCINSHAE), an event held in Mexico City that brought together officials from the country's national health institutes. Research, he said, should not stop at scientific publications but instead advance toward technologies, patents, medical devices, and medicines with direct application in patient care. He added that early-career researchers require mentorship and sustained support, rather than working in isolation, to help projects advance beyond the laboratory stage.

The call responds to a longstanding gap in Mexico's health innovation ecosystem: scientific output from public institutions has rarely translated into registered products or patents at scale. Kershenobich framed the push as one of three components in the ongoing transformation of the National Health System, alongside expanding coverage of care and medicines and strengthening health infrastructure. To close that gap, he said Mexico needs to build a research-to-market pipeline that links public institutions, universities, companies, and investment sources under a modernized regulatory framework aligned with international standards.

Regulatory modernization was one of the more concrete elements Kershenobich addressed, though the scope remains undefined. He called for faster, more efficient authorization processes and closer alignment with international standards. Financing was the other pending piece, with Kershenobich pointing to the need for mechanisms that can carry early-stage scientific ideas through to commercial or clinical application, along with short-term placements for researchers at pharmaceutical and medical device companies.

The framework builds on cooperation agreements already underway. On May 22, the Ministry signed a memorandum of understanding with the University of Illinois System to expand joint research, technology transfer, and workforce training, with initial focus areas including diabetes, obesity, cancer, and immune system diseases. That agreement follows a collaboration the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) began with the same university system in March 2025. Carlos Hinojosa, Head, CCINSHAE, said the Illinois partnership is structured around seed projects with shared funding and participation, and noted that turning research into a marketable product requires time, infrastructure, and specialized support.

The public-private link Kershenobich described is already active in Mexico's pharmaceutical sector, where multinational companies have deepened research ties with national institutes. Boehringer Ingelheim, for example, maintains active collaborations with INCMNSZ, the National Cancer Institute, the National Institute of Respiratory Diseases, and the Mexican Social Security Institute as part of a broader increase in clinical research investment the company plans for 2026, alongside similar commitments from Pfizer, Novartis, and Roche. That trend reflects a wider debate within Mexico's health sector over how intellectual property protections and regulatory frameworks should evolve to keep the country competitive for research investment while preserving access to medicines.

The scope, for now, is limited to identifying priorities and mechanisms the Ministry considers necessary to strengthen the transfer of scientific knowledge toward health products. The next phase will determine how these stated priorities translate into concrete instruments, including funding allocations, project-selection processes, and the responsibilities of participating institutions.